Clear Cell Ovarian Cancer Market

• The rate of new cases of ovarian cancer was 11.2 per 100,000 women per year. The death rate was 6.7 per 100,000 women per year. These rates are age-adjusted and based on 2013–2017 cases and 2014–2019 deaths.
• In 2018, there were an estimated 235,081 women living with ovarian cancer in the United States. (Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Ovary Cancer. National Cancer Institute, 2020)
• The earlier ovarian cancer is caught, the better chance a person has of surviving five years after being diagnosed. For ovarian cancer, 15.7% are diagnosed at the local stage. The 5-year relative survival for localized ovarian cancer is 92.6%.
• Clear Cell Ovarian Cancer epidemiology is segmented as Total Clear Cell Ovarian Cancer Incident Cases, Clear Cell Ovarian Cancer Mutation-specific Incident Cases, Clear Cell Ovarian Cancer Stage-specific Incident Cases, Clear Cell Ovarian Cancer Diagnosed and Treatable Cases in the Clear Cell Ovarian Cancer market report.

Request for unlock CAGR of Clear Cell Ovarian Cancer Market

DelveInsight's "Clear Cell Ovarian Cancer — Market Insights, Epidemiology, and Market Forecast — 2032" report delivers an in-depth understanding of the Clear Cell Ovarian Cancer, historical and forecasted epidemiology as well as the Clear Cell Ovarian Cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Clear Cell Ovarian Cancer market report provides current treatment practices, emerging drugs, Clear Cell Ovarian Cancer market share of the individual therapies, current and forecasted Clear Cell Ovarian Cancer market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Clear Cell Ovarian Cancer treatment practice/algorithm, and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States
• EU4 (Germany, Spain, Italy, and France) and the United Kingdom
• Japan

Study Period: 2019-2032

Clear Cell Ovarian Cancer Market Disease Understanding and Treatment Algorithm

The DelveInsight’s Clear Cell Ovarian Cancer market report gives a thorough understanding of Clear Cell Ovarian Cancer by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. Ovarian cancer is a disease that affects women originates in the ovaries, or in the related areas of the fallopian tubes and the peritoneum. In this form of cancer, certain cells in the ovary become abnormal and multiply uncontrollably to form a tumor. The ovaries are the female reproductive organs in which egg cells are produced. In about 90 percent of cases, ovarian cancer occurs after age 40, and most cases occur after age 60.

In its early stages, ovarian cancer usually does not cause noticeable symptoms. As the cancer progresses, signs and symptoms can include pain or a feeling of heaviness in the pelvis or lower abdomen, bloating, feeling full quickly when eating, back pain, vaginal bleeding between menstrual periods or after menopause, or changes in urinary or bowel habits. However, these changes can occur as part of many different conditions. Having one or more of these symptoms does not mean that a woman has ovarian cancer.

The ovaries are mainly made up of three kinds of cells. Each type of cell can develop into a different type of tumor i.e. epithelial ovarian carcinomas, germ cell tumors, and stromal cell tumors. Epithelial tumors start from the cells that cover the outer surface of the ovary. Most ovarian tumors are epithelial cell tumors. Germ cell tumors start from the cells that produce the eggs (ova). Stromal tumors start from structural tissue cells that hold the ovary together and produce the female hormones estrogen and progesterone. Some of these tumors are benign (non-cancerous) and never spread beyond the ovary. Malignant (cancerous) or borderline (low malignant potential) ovarian tumors can spread (metastasize) to other parts of the body and can be fatal.

Based on morphological criteria, Epithelial ovarian cancer (EOC) has been divided into subtypes: serous, endometrial, mucinous, and clear cell, representing tissues of the reproductive tract.

Ovarian clear cell carcinoma (OCCC) is the second most common subtype after high-grade serous carcinoma (HGSC). The biology and clinical behavior of OCCC are distinct from other EOCs. OCCC has a unique genetic profile characterized by frequent ARID1A and PIK3CA mutations, MET amplification, and rare p53 mutation.

Clear Cell Ovarian Cancer Diagnosis

Clear cell carcinoma of the ovary is a rare and distinct histotype of epithelial ovarian carcinomas. Women diagnosed with clear cell carcinomas are usually younger and diagnosed at earlier stages than those with the most common high-grade serous histology. Endometriosis is considered a main risk factor for the development of clear cell carcinoma of the ovary, and it can be considered a precursor of this tumor, as it is identified in more than 50% of patients with clear cell carcinoma. Women who have symptoms concerning for ovarian cancer should undergo a physical examination, transvaginal ultrasonography, and measurement of biomarkers such as cancer antigen 125. If results are suspicious for ovarian cancer, the patient should be referred to a gynecologic oncologist.

Clear Cell Ovarian Cancer Treatment

The efficacy of platinum-based chemotherapy is only 20% to 50% for OCCC. For early-stage OCCC, comprehensive surgical staging is performed, including bilateral salpingo-oophorectomy, total hysterectomy, pelvic and periaortic lymphadenectomy, omentectomy, and peritoneal biopsies. Since CCCO is considered to be a high risk group, adjuvant chemotherapy has been recommended even if the stage is IA.

Clear Cell Ovarian Cancer Epidemiology

The Clear Cell Ovarian Cancer epidemiology section provides insights about historical and current Clear Cell Ovarian Cancer patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Clear Cell Ovarian Cancer epidemiology scenario in the 7MM covering the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan from 2019 to 2032.

According to the Surveillance, Epidemiology, and End Results Program, Cancer Stat Facts: Ovary Cancer, 2020:-

• The rate of new cases of ovarian cancer was 11.2 per 100,000 women per year. The death rate was 6.7 per 100,000 women per year. These rates are age-adjusted and based on 2013–2017 cases and 2014–2019 deaths.

• In 2018, there were an estimated 235,081 women living with ovarian cancer in the United States. (Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Ovary Cancer. National Cancer Institute, 2020)

• The earlier ovarian cancer is caught, the better chance a person has of surviving five years after being diagnosed. For ovarian cancer, 15.7% are diagnosed at the local stage. The 5-year relative survival for localized ovarian cancer is 92.6%.

• The disease epidemiology covered in the report provides historical as well as forecasted Clear Cell Ovarian Cancer epidemiology [segmented as Total Incident Cases of Ovarian Cancer, Mutation-specific Incident Cases of Clear Cell Ovarian Cancer, Stage-specific Incident Cases of Clear Cell Ovarian Cancer, Diagnosed and Treatable Cases of Clear Cell Ovarian Cancer] in the 7MM covering the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan from 2019 to 2032.

Country Wise- Clear Cell Ovarian Cancer Epidemiology

This section provides a glimpse of the Clear Cell Ovarian Cancer epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Learn more about the evolving epidemiology trends and key developments: Clear Cell Ovarian Cancer Epidemiology Forecast

 

Clear Cell Ovarian Cancer Drug Chapters

The drug chapter segment of the Clear Cell Ovarian Cancer report encloses the detailed analysis of Clear Cell Ovarian Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Clear Cell Ovarian Cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Clear Cell Ovarian Cancer Marketed Drugs

At present, Avastin (bevacizumab; Genentech), Zejula (niraparib; GlaxoSmithKline), Rubraca (Clovis Oncology), Lynparza (AstraZeneca), Ethyol (amifostine; Clinigen Group), Hycamtin (topotecan hydrochloride; Novartis), Doxil (Ortho Biotech), and Paraplatin (Bristol-Myers Squibb) are a few approved drug therapies for the treatment of Ovarian Cancer. Rubraca (Clovis Oncology) and Lynparza (AstraZeneca), are a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

Note: Detailed Current therapies assessment will be provided in the full report of Clear Cell Ovarian Cancer

Clear Cell Ovarian Cancer Emerging Drugs

Rucaparib, by Clovis an oral, small molecule inhibitor of poly (ADP-ribose) polymerase (PARP)1, 2 and 3 is being developed in multiple tumor types, including ovarian and prostate cancers, as monotherapy and in combination with other anti-cancer agents. Exploratory studies in other tumor types are also underway. Rucaparib in patients with ovarian cancer study completed enrollment. The pivotal Phase III ATHENA study in first-line maintenance treatment to evaluate rucaparib in combination with nivolumab in newly diagnosed patients with stage III/IV high-grade ovarian, fallopian tube or primary peritoneal cancer who have completed platinum-based chemotherapy. The 1000 patient study will provide data from two independent readouts: rucaparib monotherapy versus placebo (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO). This Clovis sponsored study is part of an ongoing clinical collaboration with Bristol Myers Squibb.

Olvimulogene nanivacirepvec (Olvi-Vec), drug by Genelux Corporation is an oncolytic vaccinia virus-based immunotherapy. The company announced data from the Phase II VIRO-15 study evaluating its lead oncolytic virus, Olvi-Vec-primed immunochemotherapy in platinum-resistant/refractory ovarian cancer (PRROC). The Phase II data in PRROC patients demonstrated remarkable overall survival in combination with a platinum-based regimen, especially in the difficult-to-treat platinum-refractory disease population, considering these patients were heavily pretreated and largely at pre-hospice stage. The company is initiating a Phase III registration study in the US to evaluate the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the active comparator arm with platinum-doublet chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer, the recruitment is not yet started.

Note: Detailed emerging therapies assessment will be provided in the full report of Clear Cell Ovarian Cancer

Clear Cell Ovarian Cancer Market Outlook

The treatment goal of Ovarian Cancer usually is to kill the cancer cells or remove the tumor so that the cancerous cells do not metastasize and to prevent the recurrence of cancer and slow down growth. Sometimes the aim is to treat the symptoms in incurable cases by using chemotherapy, radiation, hormonal therapies, targeted drugs or a combination of any of these as per the requirement. In case of early-stage clear cell ovarian cancer, surgery is performed to remove the tumor and stage cancer followed by chemotherapy to prevent recurrence of ovarian cancer or to shrink the tumor if the tumor could not be removed by surgery. The aim is to increase the survival rate. In advanced stages of cancer (Stage III and IV) the focus is to put the tumor into remission so that it shrinks or disappears. In the case of cancer relapse, Chemotherapy is again used as a treatment option.

Once the ovarian cancer is diagnosed in a patient, the treatments are given according to the stage the patient has been diagnosed at. There are several ways of treating ovarian cancer, depending on its type and stage.

Systemic Treatments: The main objective of this therapy is to get rid of cancer cells that may have spread from the ovaries to other parts of the body.

• Primary Therapy for Stage I: The recommended regimen as per NCCN is placitaxel/carboplatin given once every 3 weeks and other recommended regimens are carboplatin/liposomal doxorubicin and docetaxel/carboplatin.

• Primary Therapy for Stage II-IV: The recommended regimen as per NCCN is placitaxel/carboplatin given once every 3 weeks or placitaxel/carboplatin/bevacizumab + maintenance bevacizumab. The other recommended regimens are placitaxel weekly/carboplatin weekly, docetaxel/carboplatin, carboplatin/liposomal doxorubicin and placitaxel weekly/carboplatin once every three weeks.

• PARP inhibitors: Post primary treatment BRCA1/2 mutated clear cell carcinoma benefit from the PARPi if  CR or PR is achieved after primary treatment with surgery and platinum based first-line therapy. The PARPi regimen used are Olaparib + bevacizumab, niraparib monotherapy, olaparib monotherapy , and rucaparib.

• Recurrence therapy for Platinum-sensitive: The treatment is dependent on clinical or biological relapse. In case of clinical relapse, first consider second cytoreductive surgery followed by combination platinum based chemotherapy. In case of biological relapse, delay the treatment until clinical relapse or immediate platinum-based recurrence therapy.

• Recurrence therapy for Platinum-resistant: The preferred regimen consists of cytotoxic therapy and targeted therapy.

• Cytotoxic Therapy: Cytotoxic drugs such as cyclophosphamide, docetaxel, gemcitabine, etoposide etc. are used.

• Targeted Therapy: Single agents such as olaparib, niraparib, rucaparib etc. are used

The improved definition of ovarian clear cell carcinoma, and greater understanding of its molecular characteristics, provide opportunities to develop alternative treatment strategies with the aim of improving survival, particularly of patients with advanced-stage or recurrent disease. Due to the rarity of clear cell carcinoma, international collaboration will be essential to power large-scale clinical trials required to answer the many remaining questions regarding the optimal treatment of this disease. Accurate diagnosis, particularly the exclusion of clear cell carcinoma mimics such as high-grade serous carcinoma with clear cells, will be crucial for these trials to produce reliable findings. Specific areas that merit further investigation include the relationship between mismatch repair (MMR) deficiency and response to immune checkpoint inhibitors, the prevalence of BRCA mutation and its relationship to poly-ADP ribose polymerase (PARP) inhibitor response, and the development of novel therapies based on tumor biology.

The dynamics of the Clear Cell Ovarian Cancer market is anticipated to change in the coming years owing to the improvement in the rise in the number of healthcare spending across the world. Key players, such as Clovis, Xencor, Genelux Corporation and some others are involved in developing drugs for Clear Cell Ovarian Cancer. The launch of potential emerging therapies such CYH33, (Haihe Biopharma), Serabelisib (Faeth Therapeutics), and XmAb20717 (Xencor) are expected to change the treatment landscape during the forecast period (2022–2032).

 According to DelveInsight, Clear Cell Ovarian Cancer market in 7MM is expected to witness a change in the study period 2019-2032.

Analyst Commentary

• The pipeline of Clear Cell Ovarian Cancer has many potential therapies that are being investigated for the treatment of Clear Cell Ovarian Cancer, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period.

• The expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and further improvement in the diagnosis rate, are likely to boost the growth of the Clear Cell Ovarian Cancer market in the 7MM. Aside from that, the market size of Clear Cell Ovarian Cancer may flourish due to increased research and development, label-expansion of approved therapies into other epilepsy in this field.

• The market growth of Clear Cell Ovarian Cancer may be offset by failures and/or discontinuation of the emerging therapies, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists.

Clear Cell Ovarian Cancer Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Clear Cell Ovarian Cancer market or expected to get launched in the market during the study period 2019-2032. The analysis covers Clear Cell Ovarian Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Note: Detailed emerging therapies assessment will be provided in the full report of Clear Cell Ovarian Cancer

Clear Cell Ovarian Cancer Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyzes Clear Cell Ovarian Cancer key players involved in developing targeted therapeutics.

Clear Cell Ovarian Cancer Clinical Trial Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Clear Cell Ovarian Cancer emerging therapies.

Reimbursement Scenario in Clear Cell Ovarian Cancer

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs ' opinions working in the Clear Cell Ovarian Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Clear Cell Ovarian Cancer market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Clear Cell Ovarian Cancer Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Clear Cell Ovarian Cancer Market Report

• The report covers the descriptive overview of Clear Cell Ovarian Cancer, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
• Comprehensive insight has been provided into the Clear Cell Ovarian Cancer epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Clear Cell Ovarian Cancer are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Clear Cell Ovarian Cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• Detailed Patient Based Market Forecasting determines the trends shaping and driving the Global Clear Cell Ovarian Cancer market

Clear Cell Ovarian Cancer Market Report Highlights

• In the coming years, the Clear Cell Ovarian Cancer market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Clear Cell Ovarian Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition     
• Major players are involved in developing therapies for Clear Cell Ovarian Cancer. The launch of emerging therapies will significantly impact the Clear Cell Ovarian Cancer market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Clear Cell Ovarian Cancer
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Clear Cell Ovarian Cancer Report Insights

• Patient Based Market Forecasting
• Therapeutic Approaches
• Clear Cell Ovarian Cancer Pipeline Analysis
• Clear Cell Ovarian Cancer Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Clear Cell Ovarian Cancer Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Clear Cell Ovarian Cancer Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Clear Cell Ovarian Cancer Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness

Key Questions

Market Insights:

• What was the Clear Cell Ovarian Cancer drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Clear Cell Ovarian Cancer total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings of the market across 7MM and which country will have the largest Clear Cell Ovarian Cancer market size during the forecast period (2019-2032)?
• At what CAGR, the Clear Cell Ovarian Cancer market is expected to grow by 7MM during the forecast period (2019-2032)?
• What would be the Clear Cell Ovarian Cancer market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the Clear Cell Ovarian Cancer market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Clear Cell Ovarian Cancer?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU4 (Germany, Spain, Italy, and France) and the UK, and Japan?
• What is the historical Clear Cell Ovarian Cancer patient pool in seven major markets covering the United States, EU4 (Germany, Spain, Italy, and France) and the UK, and Japan?
• What would be the forecasted patient pool of Clear Cell Ovarian Cancer in seven major markets covering the United States, EU4 (Germany, Spain, Italy, and France) and the UK, and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about Clear Cell Ovarian Cancer?
• Out of all 7MM countries, which country would have the highest prevalent population of Clear Cell Ovarian Cancer during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the Clear Cell Ovarian Cancer treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Clear Cell Ovarian Cancer in the US, Europe, and Japan?
• What are the Clear Cell Ovarian Cancer marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies for the treatment of Clear Cell Ovarian Cancer?
• How many therapies are in-development by each company for Clear Cell Ovarian Cancer treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Clear Cell Ovarian Cancer treatment?
• What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Clear Cell Ovarian Cancer therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Clear Cell Ovarian Cancer and its status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Clear Cell Ovarian Cancer?
• What are the global historical and forecasted markets of Clear Cell Ovarian Cancer?

Reasons to buy

• The Patient Based Market Forecasting analysis will help in developing business strategies by understanding trends shaping and driving the Clear Cell Ovarian Cancer market
• Organize sales and marketing efforts by identifying the best opportunities for Clear Cell Ovarian Cancer in the US, Europe (Germany, Spain, Italy, and France) and the United Kingdom, and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the Clear Cell Ovarian Cancer market
• To understand the future market competition in the Clear Cell Ovarian Cancer market